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Research
Organophosphate (OP) pesticides damage the
developing mammalian brain through multi-
ple mechanisms that disrupt neural cell repli-
cation and differentiation, culminating in
adverse effects on behavioral performance
(Slotkin 1999, 2004, 2005). Recent studies
conﬁrm that even exposures that are not obvi-
ously symptomatic at or below the threshold
for inhibition of cholinesterase, the standard
biomarker for OP exposure and risk assess-
ment, result in neurobehavioral abnormalities
in animals (Slotkin 1999, 2004, 2005) as well
as in children (Eskenazi et al. 2007; Landrigan
2001; Rauh et al. 2006; Young et al. 2005).
Neural pathways involving acetylcholine
(ACh) appear to be among those most sensi-
tive to developmental disruption by OPs,
partly because these agents speciﬁcally direct
differentiation away from the ACh phenotype
(Jameson et al. 2006; Slotkin et al. 2001,
2007a) and also because ACh neurons appear
to be more vulnerable to toxic damage
(Slotkin 1999, 2004, 2005). In turn, deﬁcien-
cies of ACh function contribute directly to the
emergence of cognitive impairment resulting
from early-life exposure to OPs (Chanda and
Pope 1996; Jett et al. 2001; Levin et al. 2001).
By far, chlorpyrifos is the OP that has
been the most studied for developmental
neurotoxicity (Slotkin 1999, 2004, 2005).
However, because the adverse effects of these
agents do not depend solely on their shared
property of cholinesterase inhibition, the out-
comes from exposures to other members of this
pesticide class could differ; we conducted a
series of studies demonstrating disparities in the
initial neurotoxic injury and eventual synaptic
and behavioral dysfunction between chlorpyri-
fos and diazinon (Jameson et al. 2007; Roegge
et al. 2008; Slotkin et al. 2006a, 2006b, 2007c,
2008a, 2008b, 2008c; Slotkin and Seidler
2007a; Timofeeva et al. 2008). In the present
study, we expanded our focus to include
parathion, an OP that is far more systemically
toxic to the neonate than either chlorpyrifos or
diazinon (Kacham et al. 2006; Karanth and
Pope 2003; Liu et al. 1999; Slotkin et al.
2006a). At its maximum tolerated dose,
parathion produces less initial damage in the
neonatal brain than does chlorpyrifos, largely
because the maximum tolerated dose is so
much lower due to higher systemic toxicity
(Slotkin et al. 2006a). Nevertheless, there are
substantial differences between the two agents
in their impact on muscarinic ACh receptor
expression in the neonate (Guo-Ross et al.
2007; Liu et al. 1999), suggesting that they also
diverge in their ultimate effects on ACh
neurotransmission. In the present study, we
evaluated the long-term impact of neonatal
parathion exposure on parameters of ACh
synaptic function in adolescence, young adult-
hood, and full adulthood, focusing on doses
spanning the threshold for signs of systemic
toxicity: 0.1 mg/kg, a nonsymptomatic dose
that produces barely detectable (10%)
cholinesterase inhibition (Slotkin et al. 2006b),
and 0.2 mg/kg, just over the threshold for the
first signs of systemic toxicity (Slotkin et al.
2006a). Treatment was given during the imme-
diate postnatal period [postnatal days (PNDs)
1–4], a stage at which we previously found high
sensitivity of ACh systems to disruption by
chlorpyrifos or diazinon (Roegge et al. 2008;
Slotkin 1999, 2004, 2005; Slotkin et al.
2008a, 2008b; Timofeeva et al. 2008). Studies
were conducted in various brain regions that
comprise most of the major ACh projections:
frontal/parietal cortex, temporal/occipital 
cortex, hippocampus, striatum, and midbrain.
We assessed three markers related to
ACh function: activity of choline acetyl-
transferase (ChAT), cell membrane binding
of hemicholinium-3 (HC3) to the presynap-
tic high-afﬁnity choline transporter, and the
concentration of α4β2 nicotinic acetylcholine
receptors (nAChRs). ChAT is the enzyme that
synthesizes ACh; because it is a constitutive
component of ACh nerve terminals, its activity
provides an index of the development of ACh
projections (Dam et al. 1999; Happe and
Murrin 1992; Monnet-Tschudi et al. 2000;
Qiao et al. 2003; Richardson and Chambers
2005; Slotkin et al. 2001). Although HC3
binding to the choline transporter is also a
constituent of ACh nerve terminals, its expres-
sion is directly responsive to neuronal activity
(Klemm and Kuhar 1979; Simon et al. 1976),
so that comparative effects on HC3 binding
and ChAT enable the characterization of both
the development of innervation and presynap-
tic activity. These two markers have been used
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BACKGROUND: Organophosphates elicit developmental neurotoxicity through multiple mechanisms
other than their shared property as cholinesterase inhibitors. Accordingly, these agents may differ in
their effects on speciﬁc brain circuits. 
OBJECTIVES: We gave parathion to neonatal rats [postnatal days (PNDs) 1–4], at daily doses of 0.1 or
0.2 mg/kg, spanning the threshold for barely detectable cholinesterase inhibition and systemic effects.
METHODS: We assessed neurochemical indices related to the function of acetylcholine (ACh) synapses
(choline acetyltransferase, presynaptic high-afﬁnity choline transporter, nicotinic cholinergic recep-
tors) in brain regions comprising all the major ACh projections, with determinations carried out from
adolescence to adulthood (PNDs 30, 60, and 100). 
RESULTS: Parathion exposure elicited lasting alterations in ACh markers in the frontal/parietal cor-
tex, temporal/occipital cortex, midbrain, hippocampus, and striatum. In cerebrocortical areas, mid-
brain, and hippocampus, effects in males were generally greater than in females, whereas in the
striatum, females were targeted preferentially. Superimposed on this general pattern, the cerebro-
cortical effects showed a nonmonotonic dose–response relationship, with regression of the defects
at the higher parathion dose; this relationship has been seen also after comparable treatments with
chlorpyrifos and diazinon and likely represents the involvement of cholinesterase-related actions
that mask or offset the effects of lower doses. 
CONCLUSIONS: Neonatal exposure to parathion, at doses straddling the threshold for cholinesterase
inhibition, compromises indices of ACh synaptic function in adolescence and adulthood.
Differences between the effects of parathion compared with chlorpyrifos or diazinon and the non-
monotonic dose–effect relationships reinforce the conclusion that various organophosphates diverge
in their effects on neurodevelopment, unrelated to their anticholinesterase actions.
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[Online 19 May 2008]to evaluate the effects of chlorpyrifos on ACh
systems in adult rats (Liu and Pope 1996,
1998) and to characterize the immediate and
delayed effects of postnatal chlorpyrifos or
diazinon exposure (Dam et al. 1999; Rhodes
et al. 2004; Richardson and Chambers 2005;
Slotkin et al. 2001, 2006a, 2008a). Last, the
α4β2 nAChR is a key player in the ability of
ACh systems to release other neurotransmitters
involved in reward, cognition, and mood
(Buisson and Bertrand 2001, 2002; Dani and
De Biasi 2001; Fenster et al. 1999; Quick and
Lester 2002) and is also the most abundant
nAChR subtype in the mammalian brain
(Flores et al. 1992; Happe et al. 1994; Whiting
and Lindstrom 1987, 1988).
Materials and Methods
Animal treatments. All experiments were
carried out humanely and with regard for alle-
viation of suffering, with protocols approved
by the Institutional Animal Care and Use
Committee and in accordance with all federal
and state guidelines. Timed-pregnant
Sprague–Dawley rats were housed in breeding
cages, with a 12-hr light–dark cycle and free
access to food and water. On the day after
birth, all pups were randomized and redistrib-
uted to the dams with a litter size of 10 (ﬁve
males, five females) to maintain a standard
nutritional status. Because of its poor water
solubility, parathion was dissolved in dimethyl
sulfoxide (DMSO) to provide consistent
absorption (Slotkin et al. 2006a, 2006b;
Whitney et al. 1995) and was injected subcuta-
neously in a volume of 1 mL/kg once daily on
PNDs 1–4; control animals received equivalent
injections of the DMSO vehicle, which does
not itself produce developmental neurotoxicity
(Whitney et al. 1995). Doses of 0.1 and
0.2 mg/kg/day were chosen because they strad-
dle the threshold for barely detectable
cholinesterase inhibition and the ﬁrst signs of
impaired viability (Slotkin et al. 2006a,
2006b). The low dose produces 5–10% inhibi-
tion without mortality, whereas the higher
dose elicits 5–10% mortality. The PND1–4
regimen was chosen because it represents a
peak period for sensitivity to the developmen-
tal neurotoxicity of chlorpyrifos (Slotkin 1999,
2004, 2005) and because the systemic toxicity
and cholinesterase inhibition in response to
parathion have already been characterized
(Slotkin et al. 2006a, 2006b). Randomization
of pup litter assignments within treatment
groups was repeated at intervals of several days
up until weaning, coordinated with weighing
of the animals and changes of cage bedding. In
addition, dams were rotated among litters to
distribute any maternal caretaking differences
randomly across litters and treatment groups.
Offspring were weaned on PND21.
On PNDs 30, 60, and 100, one male and
one female were selected from each litter of
origin and were decapitated. The cerebellum
(including flocculi) was removed, and the
midbrain/brainstem was separated from the
forebrain by a cut rostral to the thalamus. The
striatum and hippocampus were then dis-
sected from these larger divisions, and the
midbrain and brainstem were divided from
each other. The cerebral cortex was divided
down the midline and then further sectioned
into anterior and posterior regions (frontal/
parietal cortex and temporal/occipital cortex,
respectively). The cerebellum, which is sparse
in ACh projections, was reserved for future
studies. Tissues were frozen with liquid nitro-
gen and stored at –45°C.
Assays. Tissues were thawed in 79 volumes
of ice-cold 10 mM sodium–potassium phos-
phate buffer (pH 7.4) and homogenized with a
Polytron (Brinkmann Instruments, Westbury,
NY). Duplicate aliquots of the homogenate
were assayed for ChAT using established pro-
cedures (Qiao et al. 2003, 2004). Each tube
contained 50 µM [14C]acetyl-coenzyme A as a
substrate, and activity was determined as the
amount of labeled ACh produced relative to
tissue protein (Smith et al. 1985).
For measurements of HC3 binding, the
cell membrane fraction was prepared from an
aliquot of the same tissue homogenate by
sedimentation at 40,000 × g for 15 min. The
pellet was resuspended and washed, and the
resultant pellet was assayed with established
procedures (Qiao et al. 2003, 2004), using a
ligand concentration of 2 nM [3H]HC3 with
or without 10 µM unlabeled HC3 to displace
specific binding. Determinations of nAChR
binding were carried out in another aliquot,
each assay containing 1 nM [3H]cytisine with
or without 10 µM nicotine to displace speciﬁc
binding (Slotkin et al. 2008a). Binding was
calculated relative to the membrane protein
concentration.
Data analysis. Data were compiled as
means and standard errors. Because we evalu-
ated multiple neurochemical variables that were
all related to ACh synapses, the initial compari-
sons were conducted by a global analysis of
variance (ANOVA) (data log-transformed
because of heterogeneous variance among ages,
regions, and measures) incorporating all the
variables and measurements to avoid an
increased probability of type 1 errors that
might otherwise result from multiple tests of
the same data set. Where we identiﬁed inter-
actions of treatment with the other variables,
data were then subdivided for lower-order
ANOVAs to evaluate treatments that differed
from the corresponding control. Where per-
mitted by the interaction terms, individual
groups that differed from controls in a given
region at a given age were identified with
Fisher’s protected least significant difference
test. Signiﬁcance was assumed at p < 0.05. For
convenience, some of the results are presented
as the percent change from control values, but
statistical comparisons were conducted only on
the original data. Although not shown here,
the control values for each variable were quite
similar to those published in our previous
report (Slotkin et al. 2008a).
In evaluating the magnitude of the
changes elicited by parathion administration,
it is important to note that we used entire
brain regions rather than speciﬁc nuclei, which
means that even drastic effects on a specific
population of neurons show up as smaller
changes because of dilution with unaffected
areas. Despite this limitation, we found statis-
tically significant alterations for both treat-
ment paradigms in multiple regions.
Materials. Animals were obtained from
Charles River (Raleigh, NC), and parathion
was purchased from Chem Service (West
Chester, PA). The radioisotopically labeled
compounds [14C]acetyl-coenzyme A (speciﬁc
activity 60 mCi/mmol, diluted with unlabeled
compound to 6.7 mCi/mmol), [3H]HC3
(125 Ci/mmol), and [3H]cytisine (35 Ci/
mmol) were obtained from PerkinElmer Life
Sciences (Boston, MA). All other chemicals
were purchased from Sigma Chemical Co.
(St. Louis, MO).
Results
Multivariate ANOVA examining all treat-
ments, all brain regions, all ages, both sexes,
and all three ACh synaptic measures identiﬁed
a signiﬁcant main treatment effect (p < 0.02)
as well as interactions of treatment × sex
(p < 0.03), treatment × region (p < 0.04),
treatment × region × measure (p < 0.05), and
treatment × sex × age × measure (p < 0.05).
Because the chief interactions were with sex
and region, we separated the values for males
and females and examined the treatment
effects and interactions within each region.
In the frontal/parietal cortex, the low dose
of parathion elicited a signiﬁcant overall decre-
ment in the three ACh markers in males
(Figure 1A). Raising the dose to 0.2 mg/kg
resulted in an attenuation of the effect; the
only significant change was an increase in
ChAT at PND100. In females, neonatal expo-
sure to 0.1 mg/kg parathion failed to elicit the
global decrease in ACh markers that had been
seen in males (Figure 1B). At the higher dose,
females showed a deficit in ChAT but an
increase in nAChR binding; the latter effect
was not seen in males at either dose.
In males, the more caudal cerebrocortical
regions (temporal/occipital cortex) again
showed an overall decrease across the ACh
markers (Figure 2A). As in the frontal/parietal
cortex, increasing the neonatal exposure to
0.2 mg/kg resulted in a smaller change, connot-
ing a nonmonotonic dose–effect relationship.
In the temporal/occipital cortex, females
showed significant effects at either dose of
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nAChR binding (Figure 2B).
Like the cerebrocortical regions, the
hippocampus displayed greater effects of
neonatal parathion exposure on ACh synaptic
parameters in males than in females. At either
dose, males showed an early increase in HC3
binding and a later decrement in nAChR
binding (Figure 3A). ChAT was depressed sig-
niﬁcantly on PND30 at the low dose, whereas
at the higher dose there was a smaller effect
that did not achieve statistical significance.
However, these two effects were not them-
selves statistically distinguishable from each
other. Females showed no signiﬁcant effects in
the hippocampus at either dose of parathion
(Figure 3B). The same sex selectivity was evi-
dent in the midbrain. In this region, exposure
of male neonates to 0.1 mg/kg parathion had
little or no effect on ACh markers, but raising
the dose to 0.2 mg/kg elicited significant
deﬁcits (Figure 4A). However, no signiﬁcant
effects were seen in the midbrain of females
(Figure 4B).
The effects in the striatum were distinct
from those in the other regions. Males
showed no significant net effects after neo-
natal parathion exposure (Figure 5A), whereas
females showed significant changes at either
dose (Figure 5B). At 0.1 mg/kg, there was a
transient suppression of ChAT, and then a
small, but significant overall elevation across
all three parameters by PND60, regressing to
normal values by full adulthood (PND100).
At the higher dose, we found the same tran-
sient suppression of ChAT but also signiﬁcant
upregulation of nAChR binding. The higher
dose also produced an elevation on PND60
and regression of values by PND100, except
that the decrement in HC3 binding that was
not signiﬁcant at the lower dose now became
signiﬁcant at 0.2 mg/kg.
Neonatal parathion treatment did not sig-
nificantly affect body weights in the animals
studied here on PNDs 30, 60, and 100, nor
were there any signiﬁcant differences in brain
region weights (data not shown). However, in
the preweaning period, across the entire
Slotkin et al.
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Figure 1. Effects of neonatal parathion exposure on development of ACh synaptic markers in the frontal/parietal cortex of (A) males and (B) females. Data repre-
sent means and SEs obtained from six males and six females in each treatment group at each age, presented as the percent change from control values. ANOVA
across all treatments, ages and measures: for (A), treatment, p < 0.0005; treatment × age × measure, p < 0.03; and for (B) treatment × measure, p < 0.003; treat-
ment × age × measure, p < 0.05. Lower-order ANOVAs for each dose are shown within the panel. Where there was a treatment interaction with both age and
measure in the latter test, asterisks denote individual values that differ from the corresponding control; otherwise, only the ages or measures showing main treat-
ment effects are listed. 
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Figure 2. Effects of neonatal parathion exposure on development of ACh synaptic markers in the temporal/occipital cortex of (A) males and (B) females. NS, not
signiﬁcant. Data represent means and SEs obtained from six males and six females in each treatment group at each age, presented as the percent change from
control values. ANOVA across all treatments, ages and measures: for (A), treatment × age × measure, p < 0.05; and for (B) treatment × measure, p < 0.02. Lower-
order ANOVAs for each dose are shown within the panel. Because treatment did not interact with both age and measure, only the ages or measures showing
main treatment effects are listed. 
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nAChR, p < 0.002cohort of animals (a greater number than
those used for the neurochemical studies pre-
sented here), we did ﬁnd a signiﬁcant growth
effect (p < 0.005 for treatment, p < 0.003 for
treatment × age), with the main effect con-
fined to the group receiving 0.2 mg/kg
(p < 0.0001) representing approximately a 5%
difference from control values. We also evalu-
ated large numbers of animals through
22 weeks postpartum, well beyond the period
studied here, and found small, later-emerging
deficits at either dose in females, again
amounting to about 5% (data not shown).
Discussion
There are two important conclusions from the
current results. First, nonsymptomatic devel-
opmental exposures to parathion straddling the
threshold for cholinesterase inhibition never-
theless produce lasting changes in ACh synap-
tic function. Second, although the effects of
parathion bear resemblance to those of other
OPs such as chlorpyrifos (Slotkin et al. 2001)
or diazinon (Slotkin et al. 2008a), there are
also notable differences. This reinforces the
idea that the developmental neurotoxicity of
OPs involves mechanisms other than their
shared property of cholinesterase inhibition.
Thus, although all three agents target ACh sys-
tems in the forebrain and midbrain areas com-
prising the major ACh projections, they differ
in their regional targeting and sex selectivity.
Although we observed effects in both sexes,
parathion had much more widespread effects
in males than in females, continuing a general
pattern seen with the other OPs (Slotkin et al.
2001, 2008a). We observed sex differences for
each region and compared the pattern of
effects seen with parathion exposure to those of
chlorpyrifos and diazinon. 
In the two cerebrocortical areas as well as
in the midbrain, parathion caused deﬁcits in all
ACh-related markers in males. In contrast,
females showed effects in temporal/occipital
cortex, accompanied by suppression of
nAChRs, an effect that was not seen in males.
Thus, there are two important considerations
of this set of results, namely, the strong sex dif-
ferences and the fact that many of the results
show a nonmonotonic dose–effect relation-
ship, with lesser effects of parathion at the
higher dose. Sex differences in the develop-
mental neurotoxicity of OPs are commonly
observed with chlorpyrifos and diazinon
Parathion developmental neurotoxicity
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Figure 3. Effects of neonatal parathion exposure on development of ACh synaptic markers in the hippocampus of (A) males and (B) females. Data represent means
and SEs obtained from six males and six females in each treatment group at each age, presented as the percent change from control values. ANOVA across all
treatments, ages, and measures: for (A), treatment × age × measure, p < 0.03; and for (B), not signiﬁcant. Lower-order ANOVAs for each dose are shown within the
panel. Because treatment interacted with both age and measure in males, asterisks denote individual values that differ from the corresponding control. 
20
10
0
–10
–20
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
20
10
0
–10
–20
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
A B
HC3
nAChR
ChAT
*
*
*
*
*
0.1 mg/kg 0.1 mg/kg
Treatment × age × measure, p < 0.04
30 60 100 30 60 100
PND
30 60 100 30 60 100
PND
0.2 mg/kg
Treatment × age × measure, p < 0.02
0.2 mg/kg
Figure 4. Effects of neonatal parathion exposure on development of ACh synaptic markers in the midbrain of (A) males and (B) females. NS, not signiﬁcant. Data
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Because treatment did not interact with other variables, only main treatment effects are listed. 
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0.1 mg/kg 0.2 mg/kg(Aldridge et al. 2004, 2005; Dam et al. 2000;
Levin et al. 2001, 2002; Moser et al. 1998;
Ricceri et al. 2006; Roegge et al. 2008; Slotkin
et al. 2001, 2002, 2006b 2008a, 2008b;
Slotkin and Seidler 2005, 2007b; Timofeeva
et al. 2008) and reﬂect two contributing mech-
anisms. First, these agents appear to interfere
with sexual differentiation of the brain, nar-
rowing or eliminating many of the normal sex
differences in behavioral and/or neurochemical
parameters (Aldridge et al. 2005; Levin et al.
2001; Slotkin 1999, 2004, 2005). Second,
even where the initial neurotoxicity might be
equivalent in both sexes, the subsequent repair
processes differ substantially, with females
showing a greater general capacity to offset
damage (Amateau and McCarthy 2002;
Hilton et al. 2004; McEwen 2002; Nunez and
McCarthy 2003; Slotkin et al. 2007b; Tanapat
et al. 1999). The reduction in nAChR expres-
sion in females is thus likely to represent a
component of the adaptive mechanisms
required for reprogramming of synaptic cir-
cuits that may aid in restoring function. In any
case, the adverse effects of nonsymptomatic
neonatal parathion exposure on frontal cortex
ACh circuits are likely to have important paral-
lels in behavioral performance, as these path-
ways are critically involved in attention
(Passetti et al. 2000).
A nonmonotonic dose–response relation-
ship typically connotes the existence of multiple
mechanisms of action, so that the net outcome
is a superimposition of the various dose–effect
curves, each of which occupies a different dose
range. Here, we observed greater effects of
0.1 mg/kg parathion than 0.2 mg/kg for effects
on the cerebrocortical regions in males, repeat-
ing a pattern noted earlier for chlorpyrifos and
diazinon (Levin et al. 2002; Slotkin et al.
2008a; Timofeeva et al. 2008). The likely
mechanism for the reduced effect at the higher
dose is the greater degree of cholinesterase inhi-
bition (Slotkin et al. 2006b). In the developing
brain, ACh acts as a neurotrophic factor that
promotes the survival and differentiation of its
target cells (Hohmann 2003; Lauder and
Schambra 1999; Picciotto and Zoli 2008), an
effect that can be mimicked in part by dietary
choline supplementation (Meck and Williams
1997; Montoya et al. 2000). Accordingly, a
small degree of cholinesterase inhibition, too
low to elicit systemic toxicity or other adverse
effects of ACh hyperstimulation, might offset
some of the adverse effects of parathion that
are mediated through noncholinesterase mech-
anisms operating at lower exposures. In a
recent study, Laviola et al. (2006) demon-
strated conclusively that a carefully chosen,
small dose of chlorpyrifos can accelerate some
aspects of neurodevelopment, even while
damaging other aspects. 
Neonatal parathion exposure had a less
notable effect in the hippocampus as opposed
to the cerebrocortical regions, with a reduction
in nAChRs in males as the only persistent
effect. This stands in direct contrast to the
major deﬁcits in HC3 binding seen after com-
parable treatment with chlorpyrifos (Slotkin
et al. 2001) or reductions in ChAT seen with
diazinon (Slotkin et al. 2008a). Because ACh
projections to the hippocampus provide major
contributions to visuospatial memory perfor-
mance, we clearly expect to see significant
divergence in behavioral outcomes for the three
different OPs. Indeed, we have already seen
such disparities between chlorpyrifos and diazi-
non, including different patterns of sex selectiv-
ity (Aldridge et al. 2005; Levin et al. 2001;
Roegge et al. 2008; Timofeeva et al. 2008), and
studies are currently under way for parathion.
Again, our specific finding here of deficient
nAChR expression is likely to be involved in
behavioral deﬁcits, as suppression of the α4β2
subtype in the hippocampus impairs working
memory performance (Pocivavsek et al. 2006).
In the midbrain, we again saw greater tar-
geting of males than females. Although we
found the same pattern for neonatal chlorpyri-
fos exposure (Slotkin et al. 2001), comparable
treatment with diazinon does not seem to tar-
get these projections (Slotkin et al. 2008a).
Unlike the situation in the cerebrocortical
regions, the dose–effect relationship for
parathion was monotonic, with substantially
greater effects at the higher dose. This points
out again that the net outcomes after neonatal
OP exposure are dependent on multiple factors
that may diverge in major ways depending
upon the individual agent and the brain
region, especially given that each region is at a
different maturational stage during any speciﬁc
window of exposure (Rodier 1988). Indeed,
although we studied ACh projections in all the
regions, each synaptic population originates
from cells in different brain areas that undergo
differentiation and synaptic outgrowth with
widely varying timetables (Rodier 1988). The
ACh innervation of the midbrain originates in
the pedunculopontine and dorsolateral
tegmental nuclei; that in the hippocampus
comes from the medial septal nucleus and the
nucleus of the diagonal band; the projections
to the cerebral cortex derive from nuclei of the
basal forebrain; and striatal ACh terminals pri-
marily represent interstitial ACh interneurons.
Finally, the striatum was the one region where
the long-term disruption was greater in females
than males, again continuing a regional dis-
tinction noted in our earlier work with the
Slotkin et al.
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Figure 5. Effects of neonatal parathion exposure on development of ACh synaptic markers in the striatum of (A) males and (B) females. Data represent means and
SEs obtained from six males and six females in each treatment group at each age, presented as the percent change from control values. ANOVA across all treat-
ments, ages, and measures: for (A), not signiﬁcant; and for (B) treatment × age × measure, p < 0.05. Lower-order ANOVAs for each dose are shown within the
panel. Because treatment interacted with both age and measure in females, asterisks in (B) denote individual values that differ from the corresponding control. In
addition, because of the treatment × age interaction, a lower-order test conducted for each age point identiﬁed main treatment effects on PND60 at each dose
(p < 0.05 for both 0.1 and 0.2 mg/kg). 
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treatment × age × measure, p < 0.03other OPs (Slotkin et al. 2001, 2008a). In the
present study, parathion elicited nAChR
upregulation, whereas there were deficits in
HC3 indicative of impaired synaptic activity.
This pattern is essentially identical to that seen
after either neonatal chlorpyrifos or diazinon
exposure (Slotkin et al. 2001, 2008a), so that
we would not expect to see major differences
among the three agents in behavioral outcomes
related to this set of pathways. Impaired striatal
ACh function is likely to affect a number of
related learning tasks (Legault et al. 2006;
Palencia and Ragozzino 2006).
Conclusion
Our results in the present study reinforce the
basic finding that OPs are developmental
neurotoxicants at exposures below the thresh-
old for any signs or symptoms of acute sys-
temic toxicity, and at or below the threshold
for cholinesterase inhibition. These agents
elicit persistent effects on ACh systems criti-
cally involved in learning and memory func-
tions. Although, as studied here, many of the
effects of parathion resemble those seen in
earlier work with chlorpyrifos or diazinon
(Slotkin et al. 2001, 2008a), the OPs all differ
in their regional targeting and sex selectivity,
representing the outcomes of mechanisms
that are unrelated to their shared property as
cholinesterase inhibitors. In turn, these indi-
vidual attributes likely contribute to differ-
ences in behavioral outcomes, buttressing the
need to evaluate multiple behavioral end
points in both males and females with each
agent. Further, the nonmonotonic relation-
ship seen repeatedly for effects of OPs on
both neurochemical and behavioral parame-
ters (Levin et al. 2002; Qiao et al. 2002;
Slotkin et al. 2008a; Timofeeva et al. 2008)
points out the need to pursue studies at even
lower exposures. Certainly, these results indi-
cate the inadequacy of an approach that
focuses solely on exposures at or above the
maximum tolerated dose; given the multiple
mechanisms underlying the developmental
neurotoxicity of OPs, neurobehavioral damage
may be revealed at lower doses that are devoid
of countervailing secondary effects. Finally,
although OPs in general target developing
ACh pathways, the differences in outcomes
after neonatal exposure to parathion compared
with chlorpyrifos or diazinon indicate the
need to consider each agent individually for its
propensity to elicit neurodevelopmental dam-
age, and point to the potential to design safer
members of this class of pesticides.
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